Pharsight

Drug Patents Expiring in 2040

1. Agamree patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11382922 CATALYST PHARMS Aqueous oral pharmaceutical suspension compositions
Jul, 2040

(16 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11471471 CATALYST PHARMS Aqueous oral pharmaceutical suspension compositions
Mar, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 26, 2028
Orphan Drug Exclusivity (ODE) Oct 26, 2030

Drugs and Companies using VAMOROLONE ingredient

NCE-1 date: 2027-10-27

Market Authorisation Date: 26 October, 2023

Treatment: Treatment of duchenne muscular dystrophy

Dosage: SUSPENSION;ORAL

More Information on Dosage

AGAMREE family patents

Family Patents

2. Airduo Digihaler patents expiration

AIRDUO DIGIHALER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11344685

(Pediatric)

TEVA PHARM Drug delivery device with electronics
Mar, 2040

(16 years from now)

US11439777 TEVA PHARM Drug delivery device with electronics
May, 2040

(16 years from now)

US11464923 TEVA PHARM Inhaler system
Jun, 2040

(16 years from now)

US11173259 TEVA PHARM Drug delivery device with electronics and power management
Jul, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

AIRDUO DIGIHALER family patents

Family Patents

3. Ameluz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11235169 BIOFRONTERA Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device
Oct, 2040

(16 years from now)

Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient

Market Authorisation Date: 10 May, 2016

Treatment: Topical lesion-directed and field-directed treatment of actinic keratosis of the face and scalp with photodynamic therapy by positioning an illumination device in an appropriate distance and illuminat...

Dosage: GEL;TOPICAL

More Information on Dosage

AMELUZ family patents

Family Patents

4. Armonair Digihaler patents expiration

ARMONAIR DIGIHALER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11344685

(Pediatric)

TEVA PHARM Drug delivery device with electronics
Mar, 2040

(16 years from now)

US11439777 TEVA PHARM Drug delivery device with electronics
May, 2040

(16 years from now)

US11464923 TEVA PHARM Inhaler system
Jun, 2040

(16 years from now)

US11173259 TEVA PHARM Drug delivery device with electronics and power management
Jul, 2040

(16 years from now)

US11439777

(Pediatric)

TEVA PHARM Drug delivery device with electronics
Nov, 2040

(16 years from now)

US11464923

(Pediatric)

TEVA PHARM Inhaler system
Dec, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Jul 9, 2024
New Strength (NS) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARMONAIR DIGIHALER family patents

Family Patents

5. Auvelity patents expiration

AUVELITY's oppositions filed in EPO
Can you believe AUVELITY received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10966942 AXSOME Bupropion as a modulator of drug activity
Jan, 2040

(15 years from now)

US10925842 AXSOME Bupropion as a modulator of drug activity
Jan, 2040

(15 years from now)

US10780064 AXSOME Bupropion as a modulator of drug activity
Jan, 2040

(15 years from now)

US10940124 AXSOME Bupropion as a modulator of drug activity
Jan, 2040

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Aug 18, 2025

Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient

Market Authorisation Date: 18 August, 2022

Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of AUVELITY before it's drug patent expiration?
More Information on Dosage

AUVELITY family patents

Family Patents

6. Cabtreo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11389467 BAUSCH Topical compositions
Dec, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Oct 20, 2026

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 20 October, 2023

Treatment: Topical treatment of acne vulgaris in adult and pediatric patients 12 years of age and older

Dosage: GEL;TOPICAL

More Information on Dosage

CABTREO family patents

Family Patents

7. Caplyta patents expiration

Can you believe CAPLYTA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11753419 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders
Dec, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 20, 2024
New Indication (I) Dec 17, 2024

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

NCE-1 date: 2023-12-21

Market Authorisation Date: 20 December, 2019

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

CAPLYTA family patents

Family Patents

8. Carnexiv patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11529357 LUNDBECK PHARMS LLC Injectable carbamazepine composition essentially free of 10-bromo-carbamazepine
Jan, 2040

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 7, 2023

Drugs and Companies using CARBAMAZEPINE ingredient

Market Authorisation Date: 07 October, 2016

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

CARNEXIV family patents

Family Patents

9. Daybue patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11370755 ACADIA PHARMS INC Compositions of trofinetide
Aug, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 10, 2030
New Chemical Entity Exclusivity (NCE) Mar 10, 2028

Drugs and Companies using TROFINETIDE ingredient

NCE-1 date: 2027-03-11

Market Authorisation Date: 10 March, 2023

Treatment: NA

Dosage: SOLUTION;ORAL

More Information on Dosage

DAYBUE family patents

Family Patents

10. Elucirem patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11590246 GUERBET Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process
Jan, 2040

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 21, 2027

Drugs and Companies using GADOPICLENOL ingredient

NCE-1 date: 2026-09-21

Market Authorisation Date: 21 September, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ELUCIREM family patents

Family Patents

11. Emerphed patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11464752 NEXUS PHARMS Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
May, 2040

(16 years from now)

US11090278 NEXUS PHARMS Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
May, 2040

(16 years from now)

US11241400 NEXUS PHARMS Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
May, 2040

(16 years from now)

US11571398 NEXUS PHARMS NA
May, 2040

(16 years from now)

US11478436 NEXUS PHARMS Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
May, 2040

(16 years from now)

Drugs and Companies using EPHEDRINE SULFATE ingredient

Market Authorisation Date: 17 April, 2020

Treatment: Use of ephedrine sulfate for treating hypotension

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of EMERPHED before it's drug patent expiration?
More Information on Dosage

EMERPHED family patents

Family Patents

12. Ephedrine Sulfate patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10869845 ENDO VENTURES Ephedrine compositions and methods
Jan, 2040

(15 years from now)

Drugs and Companies using EPHEDRINE SULFATE ingredient

Market Authorisation Date: 16 October, 2020

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of EPHEDRINE SULFATE before it's drug patent expiration?
More Information on Dosage

EPHEDRINE SULFATE family patents

Family Patents

13. Eprontia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11826343 AZURITY Compositions and methods for treating epilepsy, seizures and other conditions
Aug, 2040

(16 years from now)

US11633374 AZURITY Compositions and methods for treating epilepsy, seizures and other conditions
Aug, 2040

(16 years from now)

US11433046 AZURITY Compositions and methods for treating epilepsy, seizures and other conditions
Aug, 2040

(16 years from now)

Drugs and Companies using TOPIRAMATE ingredient

Market Authorisation Date: 05 November, 2021

Treatment: Indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with lennox-gastaut syndrome in patients 2 years of age ...

Dosage: SOLUTION;ORAL

How can I launch a generic of EPRONTIA before it's drug patent expiration?
More Information on Dosage

EPRONTIA family patents

Family Patents

14. Epsolay patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11865100 GALDERMA LABS LP Method for treatment of rosacea in patients aged 65 years and older
Feb, 2040

(16 years from now)

US11541026 GALDERMA LABS LP Method for treatment of rosacea
Feb, 2040

(16 years from now)

US10933046 GALDERMA LABS LP Method for treatment of rosacea in patients aged 65 years and older
Feb, 2040

(16 years from now)

US10945987 GALDERMA LABS LP Method for providing early onset of action in the treatment of rosacea
Feb, 2040

(16 years from now)

US11426378 GALDERMA LABS LP Method for long-term treatment of rosacea
Aug, 2040

(16 years from now)

US11628155 GALDERMA LABS LP Method for therapeutic treatment of rosacea
Dec, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Apr 22, 2025

Drugs and Companies using BENZOYL PEROXIDE ingredient

Market Authorisation Date: 22 April, 2022

Treatment: Topical treatment of inflammatory lesions of rosacea in adults 65 years of age and older; Topical treatment of inflammatory lesions of rosacea in adults 18 years of age and older

Dosage: CREAM;TOPICAL

More Information on Dosage

EPSOLAY family patents

Family Patents

15. Farxiga patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10973836 ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction
Mar, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Apr 30, 2024
M (M) May 8, 2026

Drugs and Companies using DAPAGLIFLOZIN ingredient

Market Authorisation Date: 08 January, 2014

Treatment: Reduction of the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction and without type ii diabetes

Dosage: TABLET;ORAL

How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage

FARXIGA family patents

Family Patents

16. Fyarro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11497737 AADI NA
Oct, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Nov 22, 2024
Orphan Drug Exclusivity (ODE) Nov 22, 2028

Drugs and Companies using SIROLIMUS ingredient

Market Authorisation Date: 22 November, 2021

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

FYARRO family patents

Family Patents

17. Genosyl patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11672938 VERO BIOTECH INC Start-up protocols for nitric oxide delivery device
Jul, 2040

(16 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 20 December, 2019

Treatment: A method of delivering nitric oxide to a patient

Dosage: GAS;INHALATION

More Information on Dosage

GENOSYL family patents

Family Patents

18. Hetlioz Lq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11202770 VANDA PHARMS INC Liquid tasimelteon formulations and methods of use thereof
Dec, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 1, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 01 December, 2020

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage

HETLIOZ LQ family patents

Family Patents

19. Igalmi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11890272 BIOXCEL NA
Jul, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Apr 5, 2025

Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 April, 2022

Treatment: Acute treatment of agitation associated with bipolar i or ii disorder by sublingual or buccal administration

Dosage: FILM;BUCCAL, SUBLINGUAL

More Information on Dosage

IGALMI family patents

Family Patents

20. Ingrezza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10940141 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Aug, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 18, 2030
New Indication (I) Aug 18, 2026

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

Market Authorisation Date: 11 April, 2017

Treatment: Treatment of tardive dyskinesia

Dosage: CAPSULE;ORAL

How can I launch a generic of INGREZZA before it's drug patent expiration?
More Information on Dosage

INGREZZA family patents

Family Patents

21. Konvomep patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11771686 AZURITY Compositions and kits for omeprazole suspension
Mar, 2040

(16 years from now)

Drugs and Companies using OMEPRAZOLE; SODIUM BICARBONATE ingredient

Market Authorisation Date: 30 August, 2022

Treatment: Short term treatment of active benign gastric ulcer

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage

KONVOMEP family patents

Family Patents

22. Liletta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11571328 MEDICINES360 NA
Sep, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Jun 29, 2026

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 26 February, 2015

Treatment: NA

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage

LILETTA family patents

Family Patents

23. Livmarli patents expiration

Can you believe LIVMARLI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11229647 MIRUM Methods for treating cholestasis
Feb, 2040

(15 years from now)

US11497745 MIRUM NA
Feb, 2040

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 29, 2026
Orphan Drug Exclusivity (ODE) Sep 29, 2028
New Patient Population (NPP) Mar 13, 2026

Drugs and Companies using MARALIXIBAT CHLORIDE ingredient

NCE-1 date: 2025-09-29

Market Authorisation Date: 29 September, 2021

Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)

Dosage: SOLUTION;ORAL

More Information on Dosage

LIVMARLI family patents

Family Patents

24. Lumakras patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11236091 AMGEN INC Solid state forms
May, 2040

(16 years from now)

US11827635 AMGEN INC Solid state forms
May, 2040

(16 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11426404 AMGEN INC Dosing of KRAS inhibitor for treatment of cancers
Sep, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 28, 2026
Orphan Drug Exclusivity (ODE) May 28, 2028

Drugs and Companies using SOTORASIB ingredient

NCE-1 date: 2025-05-28

Market Authorisation Date: 28 May, 2021

Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior system...

Dosage: TABLET;ORAL

More Information on Dosage

LUMAKRAS family patents

Family Patents

25. Lumryz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10925844 AVADEL CNS Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
Feb, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 1, 2030
New Product (NP) May 1, 2026

Drugs and Companies using SODIUM OXYBATE ingredient

Market Authorisation Date: 01 May, 2023

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

LUMRYZ family patents

Family Patents

26. Motpoly Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11337943 AUCTA Lacosamide pharmaceutical composition and dosage form thereof
Jun, 2040

(16 years from now)

Drugs and Companies using LACOSAMIDE ingredient

Market Authorisation Date: 04 May, 2023

Treatment: Treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

MOTPOLY XR family patents

Family Patents

27. Mycapssa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11141457 AMRYT Oral octreotide therapy and contraceptive methods
Dec, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Jun 26, 2023

Drugs and Companies using OCTREOTIDE ACETATE ingredient

Market Authorisation Date: 26 June, 2020

Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients while avoiding concomitant administration of levonorgestrel

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage

MYCAPSSA family patents

Family Patents

28. Nexletol patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11613511 ESPERION THERAPS INC Methods of making bempedoic acid and compositions of the same
Jun, 2040

(16 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11760714 ESPERION THERAPS INC Methods of making bempedoic acid and compositions of the same
Jun, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 21, 2025

Drugs and Companies using BEMPEDOIC ACID ingredient

NCE-1 date: 2024-02-22

Market Authorisation Date: 21 February, 2020

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

NEXLETOL family patents

Family Patents

29. Nexlizet patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11613511 ESPERION THERAPS INC Methods of making bempedoic acid and compositions of the same
Jun, 2040

(16 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11760714 ESPERION THERAPS INC Methods of making bempedoic acid and compositions of the same
Jun, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 21, 2025

Drugs and Companies using BEMPEDOIC ACID; EZETIMIBE ingredient

NCE-1 date: 2024-02-22

Market Authorisation Date: 26 February, 2020

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

NEXLIZET family patents

Family Patents

30. Opzelura patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11590138 INCYTE CORP Topical treatment of vitiligo by a jak inhibitor
Jun, 2040

(16 years from now)

US11510923 INCYTE CORP Ruxolitinib formulation for reduction of itch in atopic dermatitis
Sep, 2040

(16 years from now)

US11590137 INCYTE CORP Ruxolitinib formulation for reduction of itch in atopic dermatitis
Sep, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Sep 21, 2024
New Indication (I) Jul 18, 2025
Pediatric Exclusivity (PED) Jan 18, 2026

Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient

Market Authorisation Date: 21 September, 2021

Treatment: For the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older, in the absence of phototherapy, wherein the vitiligo affects at least one of the lower ext...

Dosage: CREAM;TOPICAL

More Information on Dosage

OPZELURA family patents

Family Patents

31. Oriahnn (copackaged) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11690845 ABBVIE Methods of administering elagolix
Aug, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 23, 2023
New Product (NP) May 29, 2023

Drugs and Companies using ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM ingredient

NCE-1 date: 2022-07-23

Market Authorisation Date: 29 May, 2020

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) using 300 mg elagolix while co-administering omeprazole

Dosage: CAPSULE;ORAL

How can I launch a generic of ORIAHNN (COPACKAGED) before it's drug patent expiration?
More Information on Dosage

ORIAHNN (COPACKAGED) family patents

Family Patents

32. Orilissa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11690845 ABBVIE Methods of administering elagolix
Aug, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 23, 2023

Drugs and Companies using ELAGOLIX SODIUM ingredient

NCE-1 date: 2022-07-23

Market Authorisation Date: 23 July, 2018

Treatment: Management of moderate to severe pain associated with endometriosis using 150 mg or 200 mg elagolix while co-administering omeprazole

Dosage: TABLET;ORAL

How can I launch a generic of ORILISSA before it's drug patent expiration?
More Information on Dosage

ORILISSA family patents

Family Patents

33. Pemazyre patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11628162 INCYTE CORP Methods of treating cancer with an FGFR inhibitor
Aug, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 17, 2025
Orphan Drug Exclusivity (ODE) Aug 26, 2029
New Indication (I) Aug 26, 2025

Drugs and Companies using PEMIGATINIB ingredient

NCE-1 date: 2024-04-17

Market Authorisation Date: 17 April, 2020

Treatment: Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib while avoiding the concomitant u...

Dosage: TABLET;ORAL

More Information on Dosage

PEMAZYRE family patents

Family Patents

34. Proair Digihaler patents expiration

PROAIR DIGIHALER's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11439777 TEVA BRANDED PHARM Drug delivery device with electronics
May, 2040

(16 years from now)

US11464923 TEVA BRANDED PHARM Inhaler system
Jun, 2040

(16 years from now)

US11173259 TEVA BRANDED PHARM Drug delivery device with electronics and power management
Jul, 2040

(16 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 31 March, 2015

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

PROAIR DIGIHALER family patents

Family Patents

35. Qdolo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11752103 ATHENA Tramadol hydrochloride solution
Sep, 2040

(16 years from now)

US11103452 ATHENA Tramadol hydrochloride solution
Sep, 2040

(16 years from now)

Drugs and Companies using TRAMADOL HYDROCHLORIDE ingredient

Market Authorisation Date: 01 September, 2020

Treatment: Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate

Dosage: SOLUTION;ORAL

More Information on Dosage

QDOLO family patents

Family Patents

36. Qinlock patents expiration

Can you believe QINLOCK received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10966966 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(16 years from now)

US11433056 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(16 years from now)

US11529336 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(16 years from now)

US11534432 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(16 years from now)

US11266635 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(16 years from now)

US11813251 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(16 years from now)

US11426390 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(16 years from now)

US11344536 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(16 years from now)

US11576904 DECIPHERA PHARMS NA
Aug, 2040

(16 years from now)

US11612591 DECIPHERA PHARMS NA
Dec, 2040

(16 years from now)

US11576903 DECIPHERA PHARMS NA
Dec, 2040

(16 years from now)

US11801237 DECIPHERA PHARMS Amorphous kinase inhibitor formulations and methods of use thereof
Dec, 2040

(16 years from now)

US11395818 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11844788 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11850241 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11850240 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11185535 DECIPHERA PHARMS Amorphous kinase inhibitor formulations and methods of use thereof
Dec, 2040

(16 years from now)

US11793795 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
Dec, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 15, 2025
Orphan Drug Exclusivity (ODE) May 15, 2027

Drugs and Companies using RIPRETINIB ingredient

NCE-1 date: 2024-05-15

Market Authorisation Date: 15 May, 2020

Treatment: Treatment of advanced gastrointestinal stromal tumor in patients having progressed from a first line administration of imatinib, a second line administration of sunitinib, and a third line administrat...

Dosage: TABLET;ORAL

More Information on Dosage

QINLOCK family patents

Family Patents

37. Recorlev patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11278547 STRONGBRIDGE Methods of treating disease with levoketoconazole
Mar, 2040

(16 years from now)

US11020393 STRONGBRIDGE Methods of treating disease with levoketoconazole
Mar, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 30, 2028

Drugs and Companies using LEVOKETOCONAZOLE ingredient

Market Authorisation Date: 30 December, 2021

Treatment: During levoketoconazole dosage titration for the treatment of cushing's syndrome in patients who concomitantly use metformin, monitoring glycemia, kidney function and vitamin b-12 and adjusting dosage...

Dosage: TABLET;ORAL

More Information on Dosage

RECORLEV family patents

Family Patents

38. Relyvrio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11583542 AMYLYX NA
Jul, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 29, 2027
Orphan Drug Exclusivity (ODE) Sep 29, 2029

Drugs and Companies using SODIUM PHENYLBUTYRATE; TAURURSODIOL ingredient

NCE-1 date: 2026-09-29

Market Authorisation Date: 29 September, 2022

Treatment: NA

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage

RELYVRIO family patents

Family Patents

39. Scemblix patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11407735 NOVARTIS Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
May, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 29, 2026
Orphan Drug Exclusivity (ODE) Oct 29, 2028

Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient

NCE-1 date: 2025-10-29

Market Authorisation Date: 29 October, 2021

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

SCEMBLIX family patents

Family Patents

40. Sunosi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11850227 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(16 years from now)

US11857528 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(16 years from now)

US11850228 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(16 years from now)

US11850226 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(16 years from now)

US11839598 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(16 years from now)

US11839599 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(16 years from now)

US11160779 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 2023-06-18

Market Authorisation Date: 17 June, 2019

Treatment: Treatment of excessive daytime sleepiness by administering solriamfetol to a subject having no, mild, moderate, or severe renal impairment; Treatment of excessive daytime sleepiness by administering s...

Dosage: TABLET;ORAL

How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage

SUNOSI family patents

Family Patents

41. Sunosi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10940133 JAZZ Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 2023-06-18

Market Authorisation Date: 17 June, 2019

Treatment: Treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in a patient with moderate renal impairment

Dosage: TABLET;ORAL

How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage

SUNOSI family patents

Family Patents

42. Sympazan patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11541002 OTTER PHARMS NA
Jan, 2040

(15 years from now)

Drugs and Companies using CLOBAZAM ingredient

Market Authorisation Date: 01 November, 2018

Treatment: Method of treating seizures

Dosage: FILM;ORAL

More Information on Dosage

SYMPAZAN family patents

Family Patents

43. Tymlos patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11255842 RADIUS HEALTH INC Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) analog
Jan, 2040

(15 years from now)

US11680942 RADIUS HEALTH INC Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) analog
Jan, 2040

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Sep 20, 2024
New Indication (I) Dec 19, 2025

Drugs and Companies using ABALOPARATIDE ingredient

Market Authorisation Date: 28 April, 2017

Treatment: Use for detecting neutralizing antibodies

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of TYMLOS before it's drug patent expiration?
More Information on Dosage

TYMLOS family patents

Family Patents

List of large molecules

1. List of Elyea large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
USD961376 REGENERON PHARMACEUTICALS, INC. Packaging
Aug, 2040

(16 years from now)

US11439758 REGENERON PHARMACEUTICALS, INC. Devices and methods for precision dose delivery
Aug, 2040

(16 years from now)

US11433186 REGENERON PHARMACEUTICALS, INC. Devices and methods for precision dose delivery
Aug, 2040

(16 years from now)

USD961377 REGENERON PHARMACEUTICALS, INC. Packaging
Aug, 2040

(16 years from now)

US11472861 REGENERON PHARMACEUTICALS, INC. Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
Aug, 2040

(16 years from now)

US11459374 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(16 years from now)

US11459373 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(16 years from now)

Ingredients: AFLIBERCEPT

2. List of Eylea large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US11053280 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(16 years from now)

US11306135 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(16 years from now)

US11299532 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(16 years from now)

US11186625 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(16 years from now)

US11174283 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(16 years from now)

US11104715 REGENERON PHARMACEUTICALS, INC. Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
Aug, 2040

(16 years from now)

Ingredients: AFLIBERCEPT